Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services (WST) delivers essential innovations in pharmaceutical packaging and injectable drug delivery systems. This page provides investors and industry professionals with timely updates on the company’s strategic developments, financial performance, and technological advancements.
Access authoritative reporting on WST’s earnings announcements, regulatory milestones, product launches, and global partnerships. Our curated news ensures you stay informed about critical developments in elastomer-based components, biologics containment, and self-injection device platforms.
Explore updates across key areas: quarterly financial results, manufacturing expansions, compliance achievements, and collaborations with healthcare leaders. Content is rigorously verified to support data-driven decisions while adhering to financial disclosure standards.
Bookmark this page for streamlined access to WST’s evolving role in advancing safe, efficient drug delivery solutions worldwide. Check regularly for unbiased insights into one of pharma packaging’s most innovative players.
West Pharmaceutical Services (NYSE: WST) launched the West Synchrony™ Prefillable Syringe (PFS) System at CPHI Worldwide and said the system will be commercially available in January 2026. The system is described as a fully verified, system-level solution for biologics and vaccines that provides a single design verification and characterization package, a single system-level drug master file and regulatory package, and single-source supply options with make-to-stock and make-to-order and low minimum order quantities.
Management positioned the offering as intended to streamline syringe selection, accelerate regulatory submissions, and secure supply chains, while also cautioning that forward-looking statements contain risks and that there is no certainty the product will achieve particular results.
West Pharmaceutical Services (NYSE: WST) will present at four upcoming investor conferences in November–December 2025. Scheduled appearances include a UBS Global Healthcare fireside chat at 9:30 AM ET on Nov 11, 2025 in Palm Beach Gardens, FL; Jefferies Global Healthcare at 10:00 AM GMT on Nov 18, 2025 in London, UK; Stephens Annual Investment Conference at 11:00 AM CT on Nov 20, 2025 in Nashville, TN; and Citi Global Healthcare at 2:30 PM ET on Dec 2, 2025 in Miami, FL.
The company said live webcasts for each event will be available in the Investors section of the company website, and replays will be accessible for approximately 90 days after each event.
West (NYSE: WST) reported Q3 2025 net sales of $804.6M, up 7.7% (organic +5.0%), and diluted EPS of $1.92 (adjusted-diluted EPS $1.96).
Management raised full-year 2025 guidance to $3.060B–$3.070B net sales and adjusted-diluted EPS to $7.06–$7.11. Q4 guidance introduced: net sales $790M–$800M and adjusted-diluted EPS $1.81–$1.86.
Segment highlights: HVP Components +16.3% (48% of sales), HVP Delivery Devices down 15.7% (one-time $19M 2024 incentive), Proprietary Products and Contract Manufacturing both grew. Nine-month cash flow metrics improved with free cash flow $293.9M.
West (NYSE: WST) will release third-quarter 2025 financial results before the market opens on Thursday, October 23, 2025 and will host a conference call the same day at 8:00 a.m. ET.
The event includes a live webcast, a slide presentation posted in the Investors section of the company website on the day of the call, and a replay available for about 90 days. Participants who wish to ask questions must register in advance to receive a dial-in number and unique PIN for question submission.
West Pharmaceutical Services (NYSE:WST), a global leader in injectable drug administration solutions, has announced its participation in three major investor conferences in September 2025:
- Wells Fargo Healthcare Conference - September 3 in Boston (3:00 PM ET)
- Deutsche Bank Healthcare Summit - September 10 in New York City
- Bank of America Global Healthcare Conference - September 24 in London (3:05 PM GMT)
Live webcasts will be available for the Wells Fargo and Bank of America presentations on the company's investor webpage, with replays accessible for 90 days following the events.
West Pharmaceutical Services (NYSE:WST) reported strong Q2 2025 results with net sales of $766.5 million, up 9.2% year-over-year, and organic growth of 6.8%. The company's diluted EPS reached $1.82, compared to $1.51 in the prior year.
The company's performance was driven by solid growth in High-Value Product (HVP) components, particularly in GLP-1 elastomer growth and Annex 1 projects. The Board approved a Q4 2025 dividend of $0.22 per share, payable on November 19, 2025.
Following strong Q2 results, WST raised its full-year 2025 guidance, projecting net sales of $3.040-3.060 billion (up from $2.945-2.975 billion) and adjusted-diluted EPS of $6.65-6.85 (increased from $6.15-6.35).
West Pharmaceutical Services (NYSE: WST) has appointed Robert McMahon as its new Chief Financial Officer, effective August 4, 2025. McMahon, who brings 34 years of healthcare industry experience, will succeed Bernard Birkett, who will transition to Senior Advisor to the CEO through year-end.
McMahon joins from Agilent Technologies, where he served as CFO since 2018, managing finance, audit, treasury, tax, investor relations, IT, and procurement. His previous roles include CFO at Hologic and various executive financial positions during a 20-year tenure at Johnson & Johnson. He currently serves as an Independent Director at OraSure Technologies since 2023.
West Pharmaceutical Services (NYSE: WST), a global leader in injectable drug administration solutions, will release its second-quarter 2025 financial results before market open on Thursday, July 24, 2025.
The company will host a conference call at 8:00 a.m. Eastern Time to discuss results and business expectations. Participants must pre-register to ask questions during the call. A slide presentation will be available in the Investors section of West's website, and a webcast replay will be accessible for approximately 90 days following the event.
West Pharmaceutical Services (NYSE: WST), a leading provider of injectable drug administration solutions, has announced its participation in two upcoming investor conferences. The company will present at the BofA Securities Annual Healthcare Conference on May 14, 2025, at 2:20 PM PT, and at the William Blair 45th Annual Growth Stock Conference on June 5, 2025, at 10:40 AM CT. Live audio webcasts will be accessible through the company's website's "Investors" section, with replays available for approximately 90 days following the events.
West Pharmaceutical Services (NYSE: WST) announced key executive leadership changes. Bernard J. Birkett, Senior Vice President and Chief Financial Officer, has announced his intention to retire this year after serving since June 2018. The company has initiated a search for his successor, with Birkett remaining as CFO during the transition period.
Additionally, Shane Campbell has been appointed as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025. Campbell joins from Carlisle Companies Inc., where he served as Chief Commercial Officer of the Construction Materials business, bringing 20 years of experience from DuPont in various senior global leadership roles.
During his tenure, Birkett played a important role in helping West navigate through global pandemic challenges, destocking complexities, and the emergence of GLP-1s. In 2022, he served as Chief Financial and Operations Officer before transitioning back to focusing solely on CFO responsibilities in April 2024.
FAQ
What is the current stock price of West Pharm Svcs (WST)?
What is the market cap of West Pharm Svcs (WST)?
